Cushing's syndrome

News

Could OMass become the UK's 'big biotech' company?

UK-based OMass Therapeutics' ambition to join the 'big biotech' ranks has been bolstered by an impressive $310m third-round financing.

News

Key pipeline drug for Lundbeck delivers in Cushing syndrome

Lundbeck has reported positive trial results with Cushing's therapy asedebart, a key R&D prospect as it faces a patent cliff in the next few years.

News

FDA declines to approve Corcept's rare disorder drug

As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to Corcept by turning down its new Cushing's drug.

News

Ubie AI aims to improve diagnosis of rare disease Cushing’s

People with the rare disease Cushing’s syndrome can sometimes take years to get a diagnosis, but a new project hopes to shorten that timeline with the help of artificial i

Could OMass become the UK's 'big biotech' company?

Key pipeline drug for Lundbeck delivers in Cushing syndrome

FDA declines to approve Corcept's rare disorder drug

Ubie AI aims to improve diagnosis of rare disease Cushing’s

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Discover a new era of healthcare panel engagement: Grounded ...

Cushing's syndrome

Editor's Picks